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Abstract
Background—The American Cancer Society (ACS), Centers for Disease Control and 
Prevention (CDC), National Cancer Institute (NCI), and North American Association of Central 
Cancer Registries (NAACCR) collaborate annually to produce updated, national cancer statistics. 
This Annual Report includes a focus on breast cancer incidence by subtype using new, national-
level data.
Methods—Population-based cancer trends and breast cancer incidence by molecular subtype 
were calculated. Breast cancer subtypes were classified using tumor biomarkers for hormone 
receptor (HR) and human growth factor-neu receptor (HER2) expression.
Results—Overall cancer incidence decreased for men by 1.8% annually from 2007 to 2011. 
Rates for women were stable from 1998 to 2011. Within these trends there was racial/ethnic 
variation, and some sites have increasing rates. Among children, incidence rates continued to 
increase by 0.8% per year over the past decade while, like adults, mortality declined. Overall 
mortality has been declining for both men and women since the early 1990’s and for children 
since the 1970’s. HR+/HER2− breast cancers, the subtype with the best prognosis, were the most 
common for all races/ethnicities with highest rates among non-Hispanic white women, local stage 
cases, and low poverty areas (92.7, 63.51, and 98.69 per 100 000 non-Hispanic white women, 
respectively). HR+/HER2− breast cancer incidence rates were strongly, positively correlated with 
mammography use, particularly for non-Hispanic white women (Pearson 0.57, two-sided P < .
001). Triple-negative breast cancers, the subtype with the worst prognosis, were highest among 
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non-Hispanic black women (27.2 per 100 000 non-Hispanic black women), which is reflected in 
high rates in southeastern states.
Conclusions—Progress continues in reducing the burden of cancer in the United States. There 
are unique racial/ethnic-specific incidence patterns for breast cancer subtypes; likely because of 
both biologic and social risk factors, including variation in mammography use. Breast cancer 
subtype analysis confirms the capacity of cancer registries to adjust national collection standards 
to produce clinically relevant data based on evolving medical knowledge.
For over 15 years, the American Cancer Society (ACS), Centers for Disease Control and 
Prevention (CDC), National Cancer Institute (NCI), and North American Association of 
Central Cancer Registries (NAACCR) have collaborated to provide the Annual Report to the 
Nation on the Status of Cancer, which contains updated cancer incidence and mortality data 
for the United States. These reports have documented a sustained decline in cancer 
mortality, starting with our first report in 1998 (1). In addition to providing contemporary 
cancer rates and trends, each report has featured an in-depth analysis of a special topic (2–
16). This Annual Report to the Nation on Status of Cancer presents newly available data on 
national breast cancer incidence rates by demographic and tumor characteristics for the four 
intrinsic molecular subtypes.
Female breast cancer mortality has a bimodal age distribution that was first identified in the 
early 1900s, with early and late age distributions at diagnosis (17). This pattern led 
researchers to postulate that there were two main types of breast cancer according to age at 
onset and hormone dependence (18). The first breast cancer type is hormone-dependent with 
peak incidence (or mode) near age 50 years, whereas the second breast cancer is hormone-
independent with peak incidence near age 60 years (18). Later research further suggested 
that these two age-based groups of breast cancers were etiologically different (19–22). 
Analyses of gene-expression profiling have confirmed two main groups of breast cancers 
which can be further separated into four molecular subtypes according to hormone receptor 
expression (HR±) and/or epithelial cell of origin (luminal or basal). There are two HR+ 
breast cancers (Luminal A and Luminal B) and two HR− cancers (human growth factor-neu 
receptor (HER2)-enriched and basal-like) (19–23). Understanding the epidemiology of 
breast cancer by subtype is critical for guiding treatment, predicting survival, and informing 
prevention activities (22,24). Gene-expression profiling is not currently standard clinical 
practice, but, for nearly a decade, testing for joint HR/HER2 status has been a routine part of 
treatment planning. The molecular subtypes can be approximated by HR/HER2 status; ie, 
Luminal A (HR+/HER2−), Luminal B (HR+/HER2+), HER2-enriched (HR−/HER2+), and 
triple-negative (HR−/HER2−) (19,21,22,25,26).
Routine clinical care includes identifying breast cancer tumor marker expression (23,27), 
and beginning with cases diagnosed in 2010, all population-based cancer registries in the 
United States are required to report both HR and HER2 status for breast cancer cases, 
reflecting our current understanding of breast cancer pathogenesis. A recent, large-scale US 
analysis of breast cancer subtypes using 2010 HR/HER2 data was conducted using 17 NCI 
Surveillance, Epidemiology, and End Results (SEER) registries covering 28% of the US 
population (28). The analysis confirmed prior small studies by subtype, which documented 
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demographic patterns of the two main subtypes, showing HR+/HER2− to be the most 
common subtype and HR−/HER2− (“triple-negative”) being more common in younger 
women and non-Hispanic black women than in other age or racial/ethnic groups 
(22,25,27,29–34). This article uses the most current of data and expands the analysis to 
include data from 42 states plus the District of Columbia, covering 84% of the US female 
population. We present incidence rates for each breast cancer subtype by age group, race/
ethnicity, area-based poverty status, and state.
Methods
Data Sources, Codes, and Selection Criteria
Cancer Incidence and Mortality Data—Population-based cancer incidence data were 
obtained from NAACCR member registries that are funded by NCI’s SEER program and/or 
the CDC’s National Program of Cancer Registries (NPCR). Participating registries met 
NAACCR’s data quality criteria for the December 2013 submission cycle (35). Site and 
histology for incident invasive cancers were coded according to the International 
Classification of Diseases for Oncology (ICD-O) edition in use at the time of diagnosis, 
converted to the Third Edition (36,37), and categorized according to SEER site groups (36).
Incidence rates were calculated for all sites combined, childhood cancers (ages 0–14 and 0–
19 years), and the 15 most common cancers for each of the five major racial and ethnic 
groups (white, black, Asian and Pacific Islander [API], American Indian/Alaska Native [AI/
AN], and Hispanic) by sex, which results in the reporting of the 17 most common cancers 
among men and 18 among women. Hispanic ethnicity includes men and women from all 
races identified as Hispanic. Rates for AI/ANs were calculated for counties covered by the 
Indian Health Service’s Contract Health Service Delivery Area (CHSDA) because of the 
high-quality collection of AI/AN data in these areas (8,38).
Long-term (1992–2011) incidence trends for all racial and ethnic groups combined were 
estimated using data from the SEER-13 registries covering approximately 14% of the US 
population (39,40). Five-year (2007–2011) average annual incidence rates and five- and 10-
year (2007 –2011 and 2002–2011) incidence trends for all racial and ethnic groups 
combined, and 10-year trends for each of the five major racial and ethnic populations were 
calculated using combined data from NPCR and SEER registries. Together, participating 
registries cover 97% (for the five-year period) and 93% (for the 10-year period) of the US 
population.
Cause of death was based on death certificate information reported to state vital statistics 
offices and compiled through the National Vital Statistics System into a national file by the 
CDC’s National Center for Health Statistics (NCHS) (41). To maximize comparability 
among International Classification of Diseases (ICD) and ICD-O versions, cause of death 
was categorized according to SEER site groups (36). The underlying causes of death were 
selected according to the version of the ICD codes and selection rules in use at the time of 
death (ICD-6 to ICD-10). Death rates were calculated for all sites combined, childhood 
cancers, and the most common cancers among men and women consistent with the 
incidence analysis. In addition to joinpoint analyses for long-term trends from 1975 forward, 
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we also examined the 10-year and five-year mortality trends using both joinpoint and fixed-
interval methods to correspond with the incidence trends described earlier.
Population Data—Population estimates from the Census Bureau’s Vintage 2011 National 
Tables were used with SEER*Stat software to produce mortality and incidence rates by age, 
sex, race, and ethnicity (42,43). Bridged single-race population estimates produced by the 
Census Bureau in collaboration with the NCHS (44) were used in racial/ethnic rate 
calculations. For most states, population estimates as of July 1 of each year were used to 
calculate annual incidence rates which were presumed to reflect the average population of a 
defined geographic area for a calendar year; however, some adjustments were made to refine 
these estimates, as has been done in previous reports (2,45).
For results classified by poverty status, population estimates were grouped into three 
categories according to the percent of the population in the census-tract living below the 
federally defined poverty threshold: less than 10%, 10% to 19.99%, and 20% or greater, 
with the last category considered a severely disadvantaged area (46–48). Here, we used 
custom single-year sex and age-specific census-tract level residential population estimates 
for 2011 developed by Woods & Poole Economics, Inc., for use by the SEER program. 
These population estimates did not include information on race/ethnicity; therefore, we 
applied the census tract race/ethnicity proportions from the 2010 Census. The details of this 
approach have been described elsewhere (49,50). An additional 11 high-quality registries 
were excluded in this subanalysis because they did not report census tract-level data for the 
poverty analysis to NAACCR. Of note, these mutually exclusive racial/ethnic groups in the 
special section differ from the non-mutually exclusive racial/ethnic groupings used in the 
general rates and trends analysis.
Breast Cancer and HR/HER2 Biomarker Data
In this special analysis, invasive, female breast cancer cases (ICD-O-3 site codes C500-509 
excluding histology codes 9050–9055; 9140; 9590–9992) diagnosed in 2011 in women 
under age 85 years were selected. Women over the age of 84 years were excluded because 
of concerns with denominator data for the oldest age group as well issues with using a 
broad, terminal, age 85+ years category (51,52). Cases reported to the cancer registry based 
on information only on a death certificate, an autopsy report, or by a nursing home or 
hospice were found to have a high percentage of missing HR/HER2 receptor status and 
were, therefore, also excluded. In addition, cases of unknown age, unknown Hispanic 
ethnicity, or unknown county of residence were excluded. There were too few cases among 
AI/AN to conduct analysis for this racial grouping, but these cases were included in the 
overall analysis.
The estrogen receptor (ER), progesterone receptor (PR), and human growth factor-neu 
receptor (HER2) variables were coded according to NAACCR standards (53). ER and PR 
status were combined and analyzed as a joint HR status, and four HR/HER2 categories were 
used (HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2− or “triple-negative”) to 
closely align with the four intrinsic molecular subtypes of breast cancer. Cases with ER+, 
PR+, or borderline ER or PR were classed as HR+ to align with recent changes to clinical 
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guidelines that use lower cutoffs to determine positive results (54). Cases with ER− and PR− 
were classed as HR−, hence HR−/HER2− is referred to as “triple-negative”. Cases with 
borderline HER2 results were classified as “unknown” HER2. For the first year of HER2 
reporting, completeness for all three markers was not sufficient for analysis, so analysis was 
limited to invasive cases diagnosed in 2011. Analysis was restricted to the same high-quality 
cancer registries used elsewhere in this report, but we further excluded five otherwise high-
quality registries because 20% or greater of the breast cases had unknown HR/HER2 status. 
Overall, about 10% (18 622) of the selected breast cancer cancers were classified as 
unknown HER2 status and were imputed to address potential bias because of differential 
rates of missing data (see the Statistical Methods described below).
We evaluated breast cancer rates by subtype stratified by race/ethnicity and by age, stage at 
diagnosis, grade, census tract-level poverty, and by state. We were limited by small numbers 
for many groups, so we mapped breast cancer rates by subtype by state for all race/
ethnicities combined.
Statistical Methods
Incidence and Mortality Rates and Trends—Average annual cancer incidence and 
death rates per 100 000 persons were age-standardized to the 2000 US standard population 
by the direct method (55). Corresponding 95% confidence intervals (CIs) were calculated as 
modified gamma intervals (56). For stability and reliability, rates and trends were not 
reported if the numerator included less than 10 observations for 10-year trends or less than 
16 observations for five-year trends.
Trends in age-standardized cancer incidence and death rates were analyzed using joinpoint 
regression, which involves fitting a series of joined straight lines on a logarithmic scale to 
the trends in the annual age-standardized rates with at least three data points between 
changes in joinpoints (57,58). The resulting trends of varying time periods were described 
by the slope of the line segment or annual percentage change (APC) (59). Long-term 
incidence trends were calculated using both observed and delay-adjusted SEER-13 data; 
however, descriptions of these trends were based on the delay-adjusted data, except when 
noted. Delay adjustment is a statistical method to correct for unreported (delayed) or 
updated cases and mostly affects cancers diagnosed in recent years and cancers diagnosed in 
nonhospital settings (eg, melanoma or leukemia) (60). The delay-adjustment method is not 
available for NPCR areas; therefore, five-year and 10-year trends by race and ethnicity were 
based on observed NPCR and SEER combined data and not delay adjusted. We used the t 
test and the Z test, respectively, to assess whether the APC and the average annual percent 
change (AAPC) were statistically different from zero. All statistical tests were two-sided. In 
describing trends, the terms “increase” or “decrease” were used when the slope (APC or 
AAPC) of the trend was statistically significant (P < .05). For non-statistically significant 
trends, terms such as “stable,” “statistically non-significant increase,” and “statistically non-
significant decrease” were used. More detailed information on our statistical methods is 
described in previous reports (2).
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Breast Cancer Subtype Analysis—To correct for potential bias because of missing 
data in our study, we employed sequential regression multivariate imputation to impute 
missing HER2 status and all other covariates in the model with missing information, similar 
to methods used previously (28,61,62). The covariates in the imputation model include age 
at diagnosis, stage at diagnosis, race, ethnicity, registry, reporting source, ER status, PR 
status, tumor grade, tumor size, tumor histology, surgery, and county-based poverty 
category and county-based metro/nonmetro (both based on US Census data). The imputation 
was repeated independently multiple times to account for imputation uncertainty, resulting 
in 10 datasets with plausible values for missing observations for HER2 and all covariates. A 
second imputation model was run on the subset of registries that reported census tract-level 
poverty for the area-based poverty analysis.
Each imputed data set was used to obtain age-specific or age-adjusted rates per 100 000 
person-years for the four breast cancer subtypes using SEER*Stat software (39). A final 
age-specific rate and standard error was obtained by combining the age-specific rates and 
standard errors obtained from each multiply imputed data set using Rubin’s rule (63). 
Additional information on this approach is described elsewhere (62).
For state maps by subtypes, state rates were considered to be statistically significantly 
different from the nation if the 95% confidence intervals for the state did not overlap the 
national rate (64). We conducted a post hoc, exploratory analysis evaluating the relationship 
between state-level breast cancer rates by subtype and mammography and between subtype 
and percent minority population. State-level mammography data for year 2010 were 
obtained from CDC’s Behavioral Risk Factor Surveillance System (BRFSS) (65). 
Mammography use was defined as the age-adjusted prevalence of an exam within two years 
prior to 2010 as reported in Miller et al. (66). State-level demographic data were obtained 
from the 2010 US Census (67). We assessed the correlation between state-level rates and 
state-level risk factors using both linear (Pearson r) and nonparametric (Spearman’s ρ) 
correlation coefficients.
Results
Cancer Incidence Rate Long-Term Trends (1992–2011) for Most Common Cancers
Trend analysis based on SEER-13 data showed that overall delay-adjusted cancer incidence 
rates for all persons combined decreased by 0.5% (P < .001) per year from 2002 to 2011 
(Table 1). Among men, cancer incidence rates decreased on average by 1.8% (P = .003) 
annually from 2007 to 2011. Overall cancer incidence rates among women increased 0.8% 
(P = .003) annually from 1992 to 1998 but were stable from 1998 to 2011. Among children, 
ages 0–14 and 0–19 years, rates have increased by 0.8% (P < .001) per year over the past 
decade, continuing a trend dating from 1992.
Among men, delay-adjusted incidence rates from 2002 to 2011 decreased for seven of the 
most common cancers: prostate (−2.1 AAPC, P < .001), lung and bronchus (lung) (−2.4 
AAPC, P < .001), colon and rectum (colorectal) (−3.0 AAPC, P < .001), urinary bladder 
(bladder) (−0.6 AAPC, P = .05), stomach (−1.7 AAPC, P < .001), brain and other nervous 
system (brain) (−0.2 AAPC, P = .05), and larynx (−1.9 AAPC, P < .001) (Table 1). 
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Incidence rates among men increased for eight others: melanoma of the skin (melanoma) 
(2.3 AAPC, P < .001), non-Hodgkin Lymphoma (NHL) (0.3 AAPC, P = .02), kidney and 
renal pelvis (kidney) (2.0 AAPC, P = .01), leukemia (0.9 AAPC, P = .02), pancreas (1.2 
AAPC, P < .001), liver and intrahepatic bile duct (liver) (3.6 AAPC, P < .001), myeloma 
(1.9 AAPC, P < .001), and thyroid (5.3 AAPC, P < .001). Among women, delay-adjusted 
incidence rates decreased from 2002 to 2011 for seven of the most common cancers: lung 
(−1.0 AAPC, P = .001), colorectal (−2.7 AAPC, P < .001), ovary (−0.9 AAPC, P < .001), 
bladder (−0.9 AAPC, P < .001), cervix uteri (cervix) (−2.4 AAPC, P < .001), oral cavity and 
pharynx (oral) (−0.7 AAPC, P < .001), and stomach (−0.7 AAPC, P < .001). Incidence rates 
among women increased for eight others: corpus and uterus (uterus) (1.3 AAPC, P < .001), 
thyroid (5.8 AAPC, P < .001), melanoma (1.5 AAPC, P < .001), kidney (1.6 AAPC, P = .
007), pancreas (1.1 AAPC, P < .001), leukemia (0.6 AAPC, P < .001), myeloma (1.8 
AAPC, P = .002), and liver (2.9 AAPC, P < .001). Rates were stable for all other sites, 
including breast cancer.
Long-Term (1975–2011) Cancer Mortality Trends for All Racial and Ethnic Groups 
Combined
Overall cancer death rates have been declining since the early 1990s, with rates from 2002 
to 2011 decreasing by about 1.8% (P < .001) per year among males and by 1.4% (P < .001) 
per year among females (Table 2). Among children ages 0–14 and 0–19 years, rates have 
continued to decrease since 1975 with a 2.1 AAPC (P < .001) and 2.3 AAPC (P < .001) 
decrease, respectively, from 2002 to 2011, although decreases were briefly interrupted from 
1998 to 2002/2003. During the most recent 10 (2002–2011) and five (2007–2011) data 
years, death rates among males decreased for 10 top cancers (lung −2.6, P < .001; prostate 
−3.4, P < .001; colorectal −3.0, P < .001; leukemia −0.9, P < .001; NHL –2.3, P < .001; 
esophagus −0.5, P < .001; kidney −0.8, P < .001; stomach −3.4, P < .001; myeloma −1.1, P 
< .001; and larynx −2.5, P < .001 for 2002–2011 AAPC), whereas rates increased from 2002 
to 2011 for cancers of the pancreas (0.3 AAPC, P < .001), liver (2.6 AAPC, P < .001), 
melanoma of the skin (0.3 AAPC, P < .001), and soft tissue including heart (1.1 AAPC, P 
= .006). During the corresponding time period, death rates among females decreased for 13 
of the top cancers (lung −1.2, P < .001; breast −1.9, P < .001; colorectal −2.9, P < .001; 
ovary −2.0, P < .001; leukemia −1.2, P < .001; NHL −3.2, P < .001; brain −0.9, P < .001; 
kidney −0.9, P < .001; stomach −2.7, P < .001; cervix −1.3, P < .001; bladder −0.4, P < .
001; esophagus −1.5, P < .001; and oral −1.2, P = .004 for 2002–2011 AAPC), whereas they 
increased from 2002 to 2011 for cancers of the pancreas (0.4 AAPC, P < .001), uterus (1.0 
AAPC, P = .001), and liver (1.8 AAPC, P < .001). After decreasing for many years, cancer 
death rates stabilized between 2007 to 2011 for myeloma among females and for bladder, 
brain, and oral among males.
Cancer Incidence Rates (2007–2011) and Trends (2007–2011 and 2002–2011) by Race/
Ethnicity
Using data submitted to NAACCR from both SEER and NPCR sponsored registries, five-
year (2007–2011) average annual incidence rates and five- (2007–2011) and 10-year (2002–
2011) incidence trends are shown for the United States (Table 3). During the period between 
2007 and 2011, observed rates of all cancers combined in all racial groups were lower 
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among women than for men (412.8 vs 526.1 per 100 000). Black men had the highest 
overall cancer incidence rate (587.7 per 100 000) of any racial or ethnic group. Among 
women, whites had the highest overall cancer incidence rate during this period (418.6 per 
100 000). Prostate cancer remains the most common cancer among men in each racial and 
ethnic group and the rates were substantially higher than any other type of cancer. Lung 
cancer is the second most common cancer and colorectal the third most common cancer 
among men of all racial and ethnic groups, except in Hispanic men where these ranks 
reversed. Among women, breast cancer is the most common cancer among all racial and 
ethnic groups by a wide margin. Lung cancer is also the second most common cancer among 
women, with colorectal cancer being the third most common cancer, except among API and 
Hispanic women, where the ranks are again reversed. Rankings of other cancers for both 
men and women varied by race and ethnicity. White and Hispanic children had higher 
cancer incidence rates than children of other racial and ethnic groups.
Cancer incidence rates among men declined in each racial/ethnic group, averaging a 1.6% (P 
< .001) per year decline during the period between 2002 and 2011 with a steeper decline of 
2.9% (P = .007) per year during the most recent five years (Table 3). Cancer incidence rates 
declined among black women and Hispanic women between 2002 and 2011, −0.2 (P ≤ .001) 
and −0.6 (P = .002) AAPC, respectively, and were stable for women in all other racial/
ethnic groups. However, the incidence trend for all women combined during the 2007 to 
2011 period showed a decline, averaging 0.9% (P = .04) per year. For children age 0 to 14 
and 0 to 19 years, cancer incidence rates increased from 2002 to 2011 for whites (0.5 AAPC, 
P = .01 and 0.3 AAPC, P = .04, respectively) and non-Hispanic children (0.7 AAPC, P = .
002 and 0.5 AAPC, P = .01, respectively), decreased in AI/ANs children (−2.8 AAPC, P = .
05 and −2.5 AAPC, P = .01, respectively), and were stable for all other groups.
During the period between 2002 and 2011, the incidence rates for the four most common 
cancers in men decreased (prostate, lung, colorectal, and bladder) for all races except black 
and AI/AN men, for whom only prostate, lung, and colorectal cancers declined (Table 3). In 
addition, stomach (−1.3 AAPC, P < .001), esophageal (−1.1 AAPC, P = .04), brain (−0.7 
AAPC, P = .003), and larynx (−2.2 AAPC, P < .001) cancers declined in men for all races 
combined while kidney, pancreas, liver, and thyroid cancers increased. The trends in males 
for all races combined were consistent with these findings during the more recent 2007 to 
2011 time period, except for kidney cancer, which decreased, and pancreatic and stomach 
cancer, both of which remained stable. Of particular note was the declining trend for 
leukemia in the non-delay adjusted data from the NPCR and SEER registries, which directly 
contrasts with the increasing trend seen in the delay-adjusted SEER data (Table 1).
During the period between 2002 and 2011, lung cancer incidence declined in white, black, 
and Hispanic women while remaining stable in the other groups (Table 3). Colorectal cancer 
incidence declined in women in each racial/ethnic group (−3.2 AAPC, P < .001 for all 
women combined). Overall incidence rates for all women combined declined from 2007 to 
2011 (−0.4 AAPC, P = .04) as did ovarian (−2.9 AAPC, P < .001), bladder (−1.2 AAPC, P 
< .001), cervical (−2.0 AAPC, P < .001), brain (−1.8 AAPC, P < .001), and stomach (−1.1 
AAPC, P < .001) cancers. Cancer incidence rates for corpus and uterus (0.9 AAPC, P < .
001), thyroid (4.1 AAPC, P < .001), melanoma (1.1 AAPC, P = .03), and liver (2.9 AAPC, 
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P < .001) increased during this time period. On the other hand, breast cancer remained stable 
among white, AI/AN, and Hispanic women, although slight increases were seen in black and 
API women. Breast cancer rates were marginally higher in white women compared with 
black women (124.0 vs 120.7 per 100 000 women) and lower in other racial/ethnic groups 
(Table 3).
Current Cancer Death Rates (2007–2011) and Trends (2002–2011 and 2007–2011) by Race/
Ethnicity
For all cancer sites combined, cancer death rates for 2007 through 2011 were higher among 
men than women (211.6 vs 147.4 deaths per 100 000 men) (Table 4). Black men had the 
highest cancer death rate (269.3 deaths per 100 000 men) of any racial or ethnic group. Lung 
cancer was the leading cause of death in both men and women. Lung, prostate, and 
colorectal cancers were the leading causes of cancer death among men in every racial and 
ethnic group except API men, for whom lung, liver, and colorectal ranked highest. For 
women, the leading causes of cancer death were lung, breast, and colorectal cancers, 
although the rank order of these top three cancers varied for AI/AN and Hispanic women.
Decreases in overall cancer death rates from 2002 to 2011 were noted for men, women, and 
children in all racial and ethnic groups, except among API and AI/AN children for whom 
rates were stable (Table 4). Death rates declined between 2002 and 2011 for the most 
common cancers (lung, prostate, and colorectal) among men of all racial and ethnic groups 
except AI/AN. Death rates declined for the top three female cancers (lung, breast, and 
colorectal) among all racial and ethnic groups; except that rates were stable for lung cancer 
in API women and for colorectal cancer in AI/AN women. Death rates for liver cancer 
increased in all subgroups, except for API men, for whom rates decreased, and AI/AN and 
API women, for whom rates were stable. Pancreatic cancer death rates increased among 
white men and women. Additionally, death rates for melanoma and soft tissues increased 
among white men, and death rates from cancers of the uterus increased among white and 
black women.
HR/HER2 Breast Cancer Subtypes
A total of 178 125 (94.33%) invasive breast cancer cases in states with high quality 
registries diagnosed in 2011 met our selection criteria (Supplementary Table 1, available 
online). After imputation, the distribution of HR/HER2 status and associated variables 
across the original and the imputed datasets looked similar (Supplementary Table 1, 
available online). The imputed the r2 value from the model predicting missing HER2 status 
with available covariates was good (r2 = 0.39), indicating a good-fitting imputation model. 
The rates based on the imputed data were higher than the original data because of the 
imputation-assigned HR/HER2 status, while the general patterns of the age-specific curves 
looked similar across original and imputed datasets. Figure 1 shows the original and imputed 
rates for each subtype. The 10 imputations are indistinguishable and overlap. As expected, 
the imputed rates are higher than the original rates and the magnitude of difference increases 
with increasing age because the rates of unknown subtype increase with age. For instance, 
the absolute difference between the original and imputed rate for triple-negative breast 
cancer for ages 35 to 44 and 75–84 years are 0.2 and 6.4 per 100 000, respectively.
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Breast cancer subtype HR+/HER2− was the most common subtype, representing 72.6% of 
all cases, with an age-adjusted rate of 86.5 per 100 000; a rate six times higher than triple-
negative breast cancer rates of 15.5, seven times higher than HR+/HER2+ breast cancer rate 
of 12.4, and 16 times higher than HR−/HER2+ breast cancer rate of 5.5 (Table 5). In every 
race/ethnicity group, rates for HR+/HER2− breast cancers were higher than any other 
subtype, and HR+/HER2− rate was highest for non-Hispanic white women (92.7 per 100 
000) (Figure 2; Supplementary Table 2, available online). In women younger than age 45, 
HR+/HER2− breast cancer rates were comparable among racial/ethnic groups, but for older 
women rates of this subtype were much higher for non-Hispanic whites than other racial/
ethnic groups.
Rates for triple-negative breast cancers (HR−/HER2−) were highest among non-Hispanic 
black women compared with all other racial/ethnic groups with an age-adjusted rate of 27.2 
per 100 000 women; a rate 1.9 times higher than the non-Hispanic white rate, 2.3 times 
higher than the Hispanic rate, and 2.6 times higher than the non-Hispanic API (NHAPI) rate 
(Table 5). Triple-negative breast cancers comprised 13% of all breast cancers and were the 
second most common subtype among non-Hispanic black women in all age groups, after age 
45 among non-Hispanic white women, and after age 55 among NHAPI and Hispanic 
women. Subtype HR−/HER2+ breast cancer (5% of all breast cancers) had the lowest rates 
for all races/ethnicities, and breast cancer rates of HR+/HER2+ (10% of all breast cancers) 
were similar to triple-negative rates for all racial/ethnic groups except for non-Hispanic 
black women, where HR+/HER2+ breast cancer rates were much lower than triple-negative 
breast cancer rates.
Breast cancers of all subtypes were most commonly diagnosed at a local stage and least 
commonly diagnosed at a distant stage in all racial/ethnic groups with the highest rate a local 
stage, 63.51 per 100 000, for non-Hispanic white women (Figure 3; Supplementary Table 3, 
available online). Non-Hispanic black women had the highest rate of breast cancer 
diagnosed at distant stage across every subtype.
Differences in tumor grade were observed across breast cancer subtypes. Among HR+/
HER2− breast cancer cases, rates of moderately differentiated breast cancer were highest for 
all racial/ethnic groups, and rates of the least favorable grades, poorly differentiated and 
undifferentiated, were lowest for all groups except for non-Hispanic black women (Figure 4; 
Supplementary Table 4, available online). For all other breast cancer subtypes, rates of 
poorly/undifferentiated grade cases greatly exceeded the more favorable grades in every 
racial/ethnic group. Rates for poorly and undifferentiated cases were highest for triple-
negative breast cancers among non-Hispanic black women.
Breast cancer rates of HR+/HER2− decreased with increasing poverty for every racial and 
ethnic group with the highest rate, 98.69 per 100 000, for non-Hispanic white women living 
in low poverty areas (Figure 5; Supplementary Table 5, available online). There were no 
clear relationships between census tract-based poverty and incidence for the other subtypes 
for any race/ethnicity.
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The geographic distribution of breast cancer by subtype is shown in Figure 6. Because of 
small cell size, we were unable to stratify our state-level analysis by race/ethnicity. States 
with rates that were statistically higher or lower than the overall national rate are identifiable 
through the bar graphs to the left of the maps. State-level triple-negative breast cancers rates 
were lower in the northwest and higher in the southeast (Figure 6). Rates of HR+/HER2+ 
breast cancer were higher than the national rate in Idaho, Tennessee, and Pennsylvania and 
statistically lower in Colorado, Florida, Hawai’i, Kentucky, Maine, South Dakota, and 
Virginia. For HR−/HER2+ breast cancer, no states had rates that were statistically different 
from the national rate.
These maps were descriptive, ecologic assessments of the data. Geographic variation is 
driven by multiple individual and system-level factors, and the state-level differences must 
be interpreted with prudence. With this in mind, incidence rates of HR+/HER2− breast 
cancers were generally higher in states with higher mammography screening rates 
(Supplementary Figure 1A, available online). Correlation analysis indicated HR+/HER2− 
breast cancer rates were highly correlated with self-reported mammography rates for non-
Hispanic white women (Pearson r = 0.57, P < .001; Spearman ρ = 0.58, P < .001) and 
moderately correlated for non-Hispanic blacks, non-Hispanic API, and Hispanic women 
combined (Pearson r = .33, P = .033; Spearman ρ = 0.32, P = .037). Triple-negative cancers 
decreased with increasing percent of mammography for non-Hispanic Asian and Pacific 
Islanders (Pearson r = −0.46, P = 0.19; Spearman ρ = −0.45, P = .021), however, the cell 
counts in many states were too small to be stable. No correlations with mammography were 
identified for the other subtypes. Triple-negative breast cancer rates increased with 
increasing percent of non-Hispanic black population (Supplementary Figure 1B, available 
online), and the association was strongly correlated (Pearson r = 0.80, P < .001; Spearman ρ 
= 0.73, P < .001). No correlations with race/ethnicity were identified for other subtypes.
Discussion
Our data show cancer incidence rates have declined for several major cancers over the past 
20 years, including seven of the most common cancers in both men (prostate, lung, 
colorectal, stomach, brain, and larynx) and women (colorectal, ovary, cervix, oral, and 
stomach). After increasing for many decades because of a combination of early detection 
through mammography and changes in reproductive factors, premenopausal hormone 
replacement therapy (HRT) use, and obesity rates (68–72), breast cancer rates stabilized 
between 2002 and 2011. This recent stabilization may be driven by the abrupt decrease 
incidence between 2002 and 2003 that is likely because of reductions in the use of 
menopausal HRT (68). It has been shown that this decline in incidence has stabilized among 
white women, while rates continue to increase among black women (0.7 AAPC 2002–2011), 
narrowing the gap in incidence rates between these two groups (36). Two recent studies 
have demonstrated that the decline in overall breast cancer incidence between 2002 and 
2003 related to reduced HRT use was confined to white women, who are more likely to use 
HRT than black women (68,73,74). Additionally, the increase in black women may be 
partially because of increased mammography screening among black women, although the 
latest data show mammography rates have been fairly constant between 2000 and 2010 
(75,76).
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We have presented incidence data over different time periods and using different 
methodologies to provide the most informative picture of cancer burden in the US. In most 
cases, the multiple measures taken together demonstrate the robustness of these trends. But 
when comparing the trends from Tables 1–4 side by side, it is important to remember that 
join-point analysis calculates trends differently than fixed interval analysis, and the APC and 
the AAPC are different summary measures. Differences and advantages/disadvantages of 
using these measures are discussed elsewhere (59,77). Also, there are areas of discrepancy 
for a few sites, particularly when comparing recent trends. In general, the differences among 
the measures are in magnitude only. However, melanoma among SEER men, a site with 
some of the largest reporting delays related to often being treated solely in physicians’ 
offices, shows a recent (2008–2011), statistically nonsignificant downward trend that is not 
seen in the delay-adjusted trend. Therefore, statistical trends with reversed directions within 
the past five years should be considered in the context of the statistical method used and 
interpreted with caution.
Many factors contribute to changes in incidence rates over time, including changes in 
behavioral and environmental exposure patterns, endogenous risk factors, and improvements 
in screening methods and changes in screening behaviors. Other factors such as changes in 
disease classification or data collection procedures, variation in population estimates, and 
delays in cancer reporting can also affect observed trends over time. Many of the decreases 
in incidence (lung and, to a lesser extent bladder, oral and larynx) can be attributed to the 
substantial decline in smoking prevalence in the general population (7). Declines in 
colorectal cancer may be related to the elimination of precancerous lesions as a result of 
increased use of colonoscopy screening, while declines in prostate cancer may be related to 
more conservative recommendations for the use of prostate-specific antigen (PSA) screening 
(6,78). On the other hand, some cancers have increased in incidence over this time period. 
Some of the increases may be in part because of improved detection, increased screening, 
and better reporting of cancers (thyroid, melanoma) or changes in risk factors such as 
increasing obesity for pancreatic and uterine (4), increasing hepatitis C rates because of 
historical intravenous drug use for liver (79,80) and increased ultraviolet (UV) light 
exposure for melanoma (81). Rates change over time because of a combination of known 
and unknown factors. For instance, increasing rates of preclinical stage thyroid cancers are 
likely tied to recent changes in routine medical care (82). The increasing rates of thyroid 
cancers demonstrate unique epidemiologic patterns by histology type, gender, and age, 
which suggest the rise may be because of a combination of enhanced diagnostic procedures 
as well as an actual increase in etiologic risk, perhaps because of increased radiation 
exposure (83,84). However, although five-year survival is increasing for melanoma and 
thyroid cancers are increasing, the incidence rates for these cancers are increasing with little 
corresponding change in mortality. This suggests that the increasing incidence trends are 
largely because of overdiagnosis rather than large increases in disease risk for these cancers 
(85).
Likewise, overall cancer death rates continue to decrease in the United States, and this 
favorable trend includes men and women, children, all major racial and ethnic groups, and 
all four of the most common cancers (lung, colorectal, female breast, and prostate) and many 
other cancers. However, death rates continued to increase for some common cancers, 
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including liver, pancreas, melanoma (white men only), and uterus. Factors that contribute to 
the declining trends for the four most common cancers have been discussed in previous 
Annual Reports and include factors noted to be associated with the decreases in incidence, 
including reductions in risk factors (eg, smoking for lung cancer) and improved early 
detection and treatment (eg, screening and adjuvant chemotherapy for breast and colorectal 
cancers) (6,7). In contrast, reasons for the increasing death rates for pancreatic and liver 
cancers in both men and women, melanoma in men, and uterine cancer in women have not 
been fully elucidated. These trends are related to the concomitant increase in incidence and 
associated in part with a high prevalence of chronic infection with hepatitis C virus because 
of intravenous drug use between 1960 and 1980 for liver cancer (79,80), increased obesity 
prevalence for pancreatic and uterine cancers (4), and increased harmful ultraviolent 
radiation exposure for melanoma (81). Mortality rates for oral cancer stabilized in men, after 
decreasing since the late 1970s, likely reflecting the increase in incidence rates for HPV-
associated subsites that offsets the decrease in the rates for smoking related subsites (3).
This study used newly collected, nationwide data to present the largest, population-based 
analysis on breast cancer incidence by molecular subtype to date. Our analysis demonstrates 
that some of the observed racial/ethnic disparities in breast cancer incidence and survival are 
because of epidemiologic differences in breast cancer subtypes. Our results underscore the 
need to separate breast cancers into clinically relevant groups for surveillance and research 
to fully understand the epidemiology of this heterogeneous group of cancers and illustrate 
the need to consider reporting cancers by subtype where relevant, rather than overall organ 
site.
Our breast cancer subtype results show unique racial/ethnic specific patterns by age, by 
poverty level, by geography, and by specific tumor characteristics that generally align with 
previous results (25,27–32,86–88). Rates of HR+/HER2− breast cancer, the least aggressive 
breast cancer subtype, were the highest compared with other subtypes, and rates of this 
subtype were highest among non-Hispanic white women compared with other racial/ethnic 
groups. Also consistent with the prior studies, non-Hispanic black women had higher rates 
of the triple-negative breast cancer subtype compared with any other racial/ethnic group. 
Non-Hispanic black women had highest rates of triple-negative, the highest rates of distant 
stage disease, and the highest rates of poorly/undifferentiated grade among all the subtypes, 
all of which are associated with lower survival (89,90), and corresponds with black women 
having the highest rates of breast cancer mortality (36). Hormonal factors are related to 
breast cancer pathogenesis, but not all subtypes are equally associated with hormonal 
exposures and there are important differences in menstrual and reproduction factors among 
black and white women (74,91). All of these factors may be important contributors to the 
racial/ethnic differences in breast cancer incidence by subtype and subsequent survival.
A black-white crossover has long been observed where breast cancer rates are higher among 
non-Hispanic black women compared with non-Hispanic white women under age 40, with 
this pattern changing after age 40 when rates for non-Hispanic black women fall below rates 
for non-Hispanic white women. Clarke et al. determined that this crossover is a Simpson 
Paradox because of the traditional calculation of breast cancer rates on all subtypes 
combined (24,27,92). Our analysis confirmed that, despite the difference in magnitude of the 
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rates, the age-specific curves are essentially parallel between non-Hispanic white and non-
Hispanic black women for both HR+/HER2− and triple-negative breast cancers. Because 
HR+/HER2− and triple-negative breast cancers have different molecular, etiologic, and 
clinical profiles, we agree with Clarke and Lacey’s assertion that presenting epidemiologic 
patterns by race/ethnicity and molecular subtypes is more useful for understanding racial/
ethnic disparities in breast cancer incidence and survival than evaluating by race/ethnicity 
alone (24,92).
Incidence rates of HR+/HER2− breast cancer were highest for non-Hispanic white women, 
early stage cases, and low poverty areas, implying that disparities in access to health 
services and subsequently utilization of cancer screening may contribute to these 
differences. Despite the correlations between increasing mammography rates and increasing 
rates of HR+/HER2− breast cancer, the racial/ethnic rankings of HR+/HER2− breast cancer 
incidence rates do not fully align with current, reported mammography rate rankings. 
According to the 2010 BRFSS, non-Hispanic black women now have higher mammography 
rates than non-Hispanic white women (78.6% vs 75.4%) (66,93). However, there is some 
indication that the BRFSS overestimates mammography rates, more so for blacks than 
whites. After adjusting for overestimation, ranking of mammography use is highest in 
whites, then blacks, API, and finally Hispanics—which matches the racial/ethnic rankings 
for HR+/HER2−breast cancer incidence rates (94,95).
Rates of local stage disease were notably higher in the HR+/HER2− breast cancer subtype 
than in the other subtypes, while the rates for breast cancers diagnosed at distant stage were 
more similar among subtypes. This suggests that the substantially higher rates of HR+/
HER2− breast cancer may be partially explained by overdiagnosis (a type of early detection 
bias) and not true excess in disease occurrence. The estimated rate of overdiagnosis of breast 
cancers is controversial, with estimates ranging from 22% to 31% in recent literature 
(96,97). Diagnosing and treating these less aggressive cases presents a complex public 
health and ethical problem (70,97). Analysis by subtype for in situ breast cancers would be 
useful to assess overdiagnosis because of indolent tumors that would not become invasive; 
however, the completeness of the HR/HER2 variables for in situ cases was too low in the 
current database. Linking incidence data with mortality to assess survival and population-
based mortality by subtype will provide insight into whether the high rates of HR+/HER2− 
represent overdiagnosis of nonlethal invasive cancers or effective treatment of cancer 
detected early.
This is the first publication of state-level breast cancer incidence by subtype. Geographic 
variation is based on multiple factors including underlying demographic patterns, regional 
cultures and associated behaviors, potential reporting or coding discrepancies, access to care 
issues, as well as possible geographically distributed etiologic risk. The maps and post hoc 
analysis was descriptive and must be interpreted with these complexities in mind. Because 
of small cell size, we were unable to stratify our state-level analysis by race/ethnicity. 
Further evaluation using additional years of data stratified by race/ethnicity is required to 
explore plausible influences on geographic variation of breast cancer by subtype.
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Although rates of mammography use appear to drive HR+/HER2− breast cancer rates, 
mammography does not explain all of the geographic variation nor does it explain the 
distribution of other subtypes. There is little geographic variation for rates of HR+/HER2+ 
and HR−/HER2+ breast cancer by state. Because triple-negative breast cancers were highest 
among non-Hispanic black women, the high rates of triple-negative breast cancer in the 
South are likely driven by the race distributions and associated health behaviors in that 
region. Incidence of HR+ breast cancers are associated with reproductive factors (age at 
menarche and menopause, number of children and age of first birth, breastfeeding, and use 
of HRT) (98). Parity is protective for HR+/HER2− and long duration of breastfeeding is 
protective against triple-negative breast cancers (98), but parity without breastfeeding 
appears to increase a woman’s risk for triple-negative breast cancer (91). Non-Hispanic 
black women have more children but are less likely to breastfeed than non-Hispanic white 
women. Breastfeeding is one of the few modifiable risk factors and where targeted public 
health programs may be beneficial.
The completeness, quality, and geographic coverage of cancer incidence data exceed what is 
available for other chronic diseases. Nonetheless, variations in data quality, incomplete 
geographic or population reporting, and the complexity of estimating the underlying 
populations at risk may have influenced the results reported here. For example, reporting 
from smaller or more specialized providers may be less complete or have a lag in reporting 
time. Corrections for late reporting were incorporated into the rates and trends that included 
delay adjustment; however, this adjustment was not possible for data used to estimate five- 
and 10-year incidence trends and differing results may occur, as seen with long-term 
increasing trend for males with leukemia in the delay-adjusted data and contradictory 
decreasing trend seen in the nondelay adjusted data from more recent years. In addition, in 
2007 the Veteran’s Health Administration issued a directive focused on data use and privacy 
that decreased reporting to central cancer registries and likely underestimates cancer 
incidence rates among older men for specific sites (ie, prostate and lung) for diagnosis years 
2005 to 2008 (99). However, in recent years, registries have developed individual 
agreements with the VA to improve reporting. And it is unlikely to have had an impact on 
the results of the breast cancer subtype analysis.
Another limitation is the compatibility of the numerator and denominator data by race. Since 
2000, the Census has provided the opportunity to self-select multiple race categories, which 
created incompatibility between the classification of race in incidence and mortality data and 
the population denominators from the Census. The methods for developing single-race 
estimates from these data are complex and can create additional uncertainties in racial 
estimates and resultant rates, particularly for small areas of geography (50,100). The broad 
Hispanic and API categories may mask important epidemiologic variation in risk by country 
of origin or cultural practices (101,102).
This report also presents rates by race separately from Hispanic results. The white race 
category includes white Hispanics and the increases in the proportion of Hispanic population 
may be influencing reported trends. However, Hispanics are a heterogeneous group and 
some subgroups (notably Cubans) have rates comparable with non-Hispanic whites, while 
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other subgroups (eg, Mexicans) have lower rates (102). Shifts in demographics can 
influence trends, and our results must be interpreted with this in mind.
Long-term trends were reported based on SEER-13 registries representing only 14% of the 
US population. More geographic population coverage was available for 10- (93%) and five- 
(97%) year trends; however, some states were excluded from all analyses, which may 
influence reported rates. Interpretation of cancer incidence and mortality trends requires 
consideration of underlying risk, which includes not only etiologic risk and changes in 
behavior, but also changes in clinical and public health practice, such as introduction of or 
changes in specific diagnostic or screening tools.
In the breast cancer subtype analysis, one limitation is the completeness and quality of joint 
HR/HER2 receptor status. Approximately 5% HR status is missing in the data, but 11% of 
the cases are missing HER2 status (Supplementary Table 1, available online). The HER2 
data are newly collected, and the quality and completeness of these data have not been 
rigorously evaluated over time. With only one year of data on HER2, we were unable to 
stratify by race/ethnicity in the state-level analysis because of small numbers in many 
categories. Additional years of data will enable more detailed state-level analysis.
Limitations related to the imputation technique include lack of information on potential 
predictors of missing HER2 status, such as treatment, risk factors, and survival outcomes for 
HER2 status. Despite these limitations, the prediction model was a good fit and the 
distributions of HER2 were similar among the original and imputed datasets. Finally, this 
imputation approach assumes HER2 information was missing at random (MAR). Although 
this assumption is not testable, the MAR assumption has been shown to be plausible when 
imputing missing information for breast cancer tumor markers such as ER status from 
population-based cancer registries (21,62). Inspection of missing HER2 data pattern 
suggests we have met the MAR assumption, as there is varying degree of missingness that 
seem to be explained by the different covariates (data not shown). In practice, however, we 
acknowledge that we cannot empirically test the MAR assumption.
The United States has made considerable strides in reducing the burden of cancer for many 
sites, notably the tobacco-related cancers. However, it is important to note that a decreasing 
age-adjusted trend may correspond to an increasing number of individuals with cancer in 
certain age groups. Despite our successes, cancer remains a major burden and support for 
the clinical and public health infrastructure for diagnosing, treating, prevention, and tracking 
cancer remain vital.
Although population-based screening is an important component for reducing breast cancer 
mortality, it may not affect mortality for every breast cancer subtype. In order to further our 
understanding of the advantages and disadvantages of continued widespread mammography 
screening, particularly for HR+/HER2− breast cancers, we need to further our clinical 
understanding of the HR+/HER2− subtype and the factors associated with disease detection 
and progression.
Numerous health and psychosocial benefits of breastfeeding are well established. Although 
the impact of increasing population- based breastfeeding rates on any specific breast cancer 
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subtypes is yet unknown, public health programs promoting breastfeeding may ameliorate 
the higher rates of triple-negative breast cancers among black women (91,98,103,104).
Because the diagnosis of cancer is continually refined based on advancements in medical 
knowledge, classification of cancers is continually evolving. For instance, we analyzed four 
breast cancer subtypes, but recent molecular research has reinforced the notion that breast 
cancer may only have two important groups—basal-like, which are predominately triple-
negative, and all others (105). Tracking HR/HER2 status for breast cancers is essential to 
determining which molecular groupings are clinically important for treatment decisions and 
which are etiologically important for public health prevention.
Biomarkers have also successfully identified subtypes of other cancers as well, notably 
leukemia and esophageal cancers. Presenting incidence, mortality, and survival rates by 
molecular or histologic subtypes will become increasingly important for understanding the 
impact of prevention, screening, and treatment of cancer in the future. Population-based 
cancer registry data will play a vital role in assessing temporal trends and identifying 
etiologic hypotheses. Cancer surveillance, both incidence and mortality, must ensure that 
data collected remains relevant in order to appropriately guide public health research and 
prevention and address the source of racial/ethnic disparities in breast as well as other 
cancers.
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Original vs imputed age-specific rates by subtype, unknown subtype for diagnosis year 
2011, and areas in the United States with high-quality incidence data*^. A) Hormone 
receptor (HR)+/ human epidermal growth factor receptor 2 (HER2)− rates per 100 000 
womenŦ. B) Triple-negative rates per 100 000 women. C) HR+HER2+ rates per 100 000 
women. D) HR−/HER2+ rates per 100 000 women. *Population-based registries meeting 
North American Association of Central Cancer Registries quality criteria and high 
completeness of HR/HER2 data include: Alaska, California, Colorado, Connecticut, 
Delaware, District of Columbia, Florida, Georgia, Hawai’i, Idaho, Illinois, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, 
Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, 
North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Carolina, 
South Dakota, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming. 
^All 10 imputations had near identical rate estimates. ŦNote: HR+/HER2− has much higher 
rates, so this figure has a different y-axis. The unknown rate is a reference rate from the 
original data and is the same for each figure. HER2 = human epidermal growth factor 
receptor 2; HR = hormone receptor.
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Age-specific incidence rates of invasive breast cancer by subtype, by race/ethnicity, for 
diagnosis year 2011, and areas in the United States with high-quality incidence data*. A) 
Age-specific rates for non-Hispanic white women. B) Age-specific rates for non-Hispanic 
black women. C) Age-specific rates for non-Hispanic Asian/Pacific Islander women. D) 
Age-specific rates for Hispanic women. *Population-based registries meeting North 
American Association of Central Cancer Registries quality criteria and high completeness of 
hormone receptor/human epidermal growth factor receptor 2 data include: Alaska, 
California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, 
Hawai’i, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, 
Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New 
Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, 
Pennsylvania, Rhode Island, South Carolina, South Dakota, Utah, Vermont, Virginia, 
Washington, West Virginia, Wisconsin, Wyoming. HER2 = human epidermal growth factor 
receptor 2; HR = hormone receptor.
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Age-adjusted incidence rates of invasive breast cancer by subtype, stage, race/ethnicity for 
diagnosis year 2011, and areas in the United States with high-quality incidence data*. A) 
HR+/HER2− rates per 100 000 womenŦ. B) Triple-negative rates per 100 000 women. C) 
HR+HER2+ rates per 100 000 women. D) Hormone receptor (HR)−/ human epidermal 
growth factor receptor 2 (HER2)+ rates per 100 000 women. Error bars represent 95% 
confidence intervals. *Population-based registries meeting North American Association of 
Central Cancer Registries quality criteria and high completeness of HR/HER2 data include: 
Alaska, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, 
Georgia, Hawai’i, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, 
Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New 
Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, 
Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Utah, Vermont, 
Virginia, Washington, West Virginia, Wisconsin, Wyoming. API = Asian/Pacific Islander; 
HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; NH=Non-
Hispanic.
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Age-adjusted incidence rates of invasive breast cancer by subtype, grade, race/ethnicity for 
diagnosis year 2011, and areas in the United States with high-quality incidence data*. A) 
Hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)− rates per 100 
000 womenŦ. B) Triple-negative rates per 100 000 women. C) HR+HER2+ rates per 100 
000 women. D) HR−/HER2+ rates per 100 000 women. Error bars represent 95% 
confidence intervals. *Population-based registries meeting North American Association of 
Central Cancer Registries quality criteria and high completeness of HR/HER2 data include: 
Alaska, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, 
Georgia, Hawai’i, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, 
Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New 
Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, 
Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Utah, Vermont, 
Virginia, Washington, West Virginia, Wisconsin, Wyoming. API = Asian/Pacific Islander; 
HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; NH=Non-
Hispanic.
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Age-adjusted incidence rates of invasive breast cancer by subtype, census tract poverty, 
race/ethnicity for diagnosis year 2011, and areas in the United States with high-quality 
incidence data reporting census tract-based poverty measure*. A) Hormone receptor (HR)+/
human epidermal growth factor receptor 2 (HER2)− rates per 100 000 womenŦ. B) Triple-
negative rates per 100 000 women. C) HR+HER2+ rates per 100 000 women. D) HR−/
HER2+ rates per 100 000 women. Error bars represent 95% confidence intervals. 
*Database with census tract-level poverty is a subset of the high quality registries who 
report tract-level poverty category: Alaska, California, Colorado, Connecticut, Delaware, 
District of Columbia, Florida, Georgia, Hawai’i, Idaho, Illinois, Indiana, Iowa, Kentucky, 
Louisiana, Maryland, Detroit, New Hampshire, New Jersey, New Mexico, New York, North 
Carolina, Ohio, Pennsylvania, Rhode Island, South Carolina, South Dakota, Utah, Vermont, 
Washington, West Virginia, Wisconsin, Wyoming. API = Asian/Pacific Islander; HER2 = 
human epidermal growth factor receptor 2; HR = hormone receptor; NH=Non-Hispanic.
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Age-specific incidence rates of invasive breast cancer by subtype for diagnosis year 2011 for 
states with high-quality incidence data. A) Hormone receptor (HR)+/human epidermal 
growth factor receptor 2 (HER2)− state rates per 100 000 womenŦ. B) Triple-negative state 
rates per 100 000 women. C) HR+HER2+ state rates per 100 000 women. D) HR−/HER2+ 
state rates per 100 000 women. Bars indicate 95% confidence interval; gray shading 
denotes tertiles (white indicates no data available). API = Asian/Pacific Islander; HER2 = 
human epidermal growth factor receptor 2; HR = hormone receptor; NH=Non-Hispanic.
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Table 5
Age-adjusted incidence rates of invasive breast cancer by subtype, race/ethnicity for diagnosis year 2011, and 
areas in the United States with high-quality incidence data*
Race/ethnicity Subtype Rate (95% CI)
All race/ethnicities HR+/HER2+ 12.4 (12.4 to 12.5)
HR−/HER2+ 5.5 (5.5 to 5.6)
HR+/HER2− 86.5 (86.5 to 86.6)
Triple-negative 15.5 (15.5 to 15.6)
Non-Hispanic white HR+/HER2+ 12.8 (12.7 to 12.8)
HR−/HER2+ 5.4 (5.3 to 5.4)
HR+/HER2− 92.7 (92.7 to 92.8)
Triple-negative 14.4 (14.4 to 14.5)
Non-Hispanic black HR+/HER2+ 12.9 (12.8 to 13.0)
HR−/HER2+ 6.7 (6.6 to 6.9)
HR+/HER2− 74.4 (74.2 to 74.6)
Triple-negative 27.2 (27.1 to 27.3)
Non-Hispanic Asian/Pacific Islander HR+/HER2+ 10.8 (10.7 to 11.0)
HR−/HER2+ 5.9 (5.9 to 6.0)
HR+/HER2− 63.9 (63.7 to 64.3)
Triple-negative 10.3 (10.1 to 10.4)
Hispanics HR+/HER2+ 10.3 (10.2 to 10.4)
HR−/HER2+ 5.1 (5.0 to 5.2)
HR+/HER2− 64.0 (63.8 to 64.1)
Triple-negative 11.8 (11.7 to 11.9)
*
Population-based registries meeting North American Association of Central Cancer Registries quality criteria and high completeness of hormone 
receptor/human epidermal growth factor receptor 2 data include: Alaska, California, Colorado, Connecticut, Delaware, District of Columbia, 
Florida, Georgia, Hawai’i, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, 
Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, 
Rhode Island, South Carolina, South Dakota, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming.
CI = confidence interval; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor.
J Natl Cancer Inst. Author manuscript; available in PMC 2015 December 01.
